Net Loss Per Share

6 Months Ended

Jun. 30, 2022

14. Net Income (Loss) Per Share

Basic and diluted net loss per share attributable to atai stockholders were calculated as follows (in thousands, except share and per share data):


	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2021			2022			2021
Numerator:
Net loss	$	(37,509	)	$	(53,373	)	$	(75,067	)	$	(49,329	)
Net loss attributable to redeemable noncontrolling interests and noncontrolling interests		(891	)		(4,912	)		(1,580	)		(1,556	)
Net loss attributable to ATAI Life Sciences N.V. shareholders - basic and diluted	$	(36,618	)	$	(48,461	)	$	(73,487	)	$	(47,773	)
Denominator:
Weighted average common shares outstanding attributable to ATAI Life Sciences N.V. Stockholders - basic and diluted		153,971,202			132,265,075			153,751,456			125,797,732
Net loss per share attributable to ATAI Life Sciences N.V. shareholders - basic and diluted	$	(0.24	)	$	(0.37	)	$	(0.48	)	$	(0.38	)

HSOP Shares issued to the Partnership and allocated to the HSOP Participants are not considered outstanding for accounting purposes and not included in the calculation of basic weighted average common shares outstanding in the table above because the HSOP Participants have a forfeitable right to distributions until the HSOP Options vest and are exercised, at which time the right becomes nonforfeitable.

The following also represents the maximum amount of outstanding shares of potentially dilutive securities that were excluded from the computation of diluted net income (loss) per share attributable to common shareholders for the periods presented because including them would have been antidilutive:

Potentially dilutive securities to the Company’s common shares:


	As of June 30,
	2022		2021
Options to purchase common stock		34,410,771		23,797,993
HSOP options to purchase common stock		7,046,496		7,281,376
2018 Convertible Promissory Notes - Related Parties (Note 10)		9,561,824		16,000,000
		51,019,091		47,079,369

The remaining 2018 Convertible Notes would be issuable upon the exercise of conversion rights of convertible note holders for 597,614 shares of common stock of ATAI Life Sciences AG, respectively. Upon conversion, it is expected that the remaining 2018 Convertible Notes would be exchanged on a one-for-sixteen basis for shares of ATAI Life Sciences N.V. which is reflected in the table above. See Note 10 for additional discussion.